Table 2.

Patient-specific clinical factors associated with a prolonged progression-free survival among all patients (N = 122).

Variable	N	No. of events	(%)	Univariable analysis		Multivariable analysis
				Crude HR (95% CI)	P-value	Adjusted HR (95% CI)	P-value
PFI
≥ 12 months	60	35	58.3	0.48 (0.29–0.80)	0.005	0.38 (0.20–0.70)	0.003
< 12 months	62	38	61.3	1		1
Response to the last platinum dose according to RECIST
Complete	20	12	60.0	0.86 (0.38–1.72)	0.701
Partial	102	61	59.8	1
CA-125 level within reference values after the last platinum dose
≤ 35 U/mL	93	51	54.8	0.40 (0.24–0.69)	0.001	0.46 (0.25–0.89)	0.016
> 35 U/mL	29	22	75.9	1		1
Age
≥ 60 years	57	32	56.1	0.98 (0.62–1.56)	0.945
< 60 years	65	41	63.1	1
NLR
≥ 3.32	18	10	55.6	1.00 (0.44–1.97)	0.994
< 3.32	104	63	60.6	1
PLR
≥ 210	37	24	64.9	1.98 (1.19–3.24)	0.007	3.10 (1.60–5.83)	0.001
< 210	85	49	57.6	1		1

HR hazard ratio, CI confidence interval, PFI platinum-free interval, RECIST Response Evaluation Criteria in Solid Tumors, CA-125 cancer antigen 125, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio.